A New Nonopioid Option for Acute Pain: Promise and Practical Limits of Suzetrigine

This is a reprint of an article from the February 2026 issue of Cleveland Clinic Journal of Medicine (2026 Feb 2;93(2):94-98).

By Anthony E. Divito, MD; Matthew Sharobeem, DO; Gausan R. Bajracharya, MD; and Basem B. Abdelmalak, MD

Opioids have been the mainstay of postoperative analgesia for decades. However, their side effects and potential complications, such as respiratory depression, postoperative nausea, vomiting and ileus, have fueled the search for alternative ways to control pain. Thus, the concept of multimodal analgesia was born — a technique using a combination of different analgesic modalities, including acetaminophen, nonsteroidal anti-inflammatories, N-methyl-D-aspartate receptor antagonists, intravenous lidocaine infusion, local anesthetic infiltration, regional anesthesia and peripheral nerve blocks, that can result in maximal pain relief with the minimum necessary dose of opioids to lessen their side effects. This strategy has coincided with the adoption of enhanced recovery after surgery protocols that have helped promote multimodal analgesia to minimize opioid use while permitting a more expedient recovery.¹

Recently, suzetrigine, a voltage-gated sodium channel 1.8 (Na_V1.8) blocker, was approved by the U.S. Food and Drug Administration (FDA), leading to interest in possibly adding this nonopioid analgesic to the multimodal analgesic regimen.

The first systemic sodium channel blocker oral analgesic

Sodium channels have long been a known target for analgesia. Local anesthetics, in particular, inhibit nerve conduction via the intracellular blockade of sodium channels. However, systemic administration of local anesthetic agents has remained limited and considered off-label use. Systemic lidocaine administration has been studied for acute postsurgical pain, but side effects stemming from nonselective inhibition of sodium channels in the heart and central nervous system, as well as a lack of evidence that it is effective beyond 24 hours postoperatively, have limited its use.^2,3

Suzetrigine is the first systemic sodium channel blocker that has been approved by the FDA for the indication of treating moderate to severe postoperative pain. If suzetrigine proves over time to be effective enough to reduce or even supplant opioids, the current workhorse, it would be a significant advancement in pain management.

Pharmacodynamics and pharmacokinetics

Suzetrigine is a highly selective sodium channel blocker that primarily targets the Na_V1.8 voltage-gated sodium channel.⁴ Its chemical name is 4-[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-4-(trifluoromethyl)oxolane-2-amido]pyridine-2-carboxamide, and in clinical trials it was referred to as VX-548.⁴ The Na_V1.8 voltage-gated sodium channel appears to be highly expressed in the dorsal root ganglia of peripheral sensory neurons but not significantly expressed in the central nervous system or the heart.^5-7 Because Na_V1.8 channels are only found in peripheral sensory neurons, there is optimism that a peripherally mediated therapeutic effect can be achieved without a significant risk of central nervous system-mediated side effects, arrhythmogenesis, or high potential for abuse and addiction.^8,9

Suzetrigine has a peak plasma time to maximum concentration of three hours in fasting conditions and a half-life of 23.6 hours; 49.9% is eliminated in feces and 44% in urine.¹⁰ There seems to be no clinically significant pharmacokinetic differences based on age, sex, body weight, race or renal impairment.

Suzetrigine is primarily metabolized by the liver into the active metabolite M6-SUZ, which is a weaker Na_V1.8 inhibitor.¹¹ Because this process is mediated through the cytochrome P450 3A (CYP3A) enzyme, suzetrigine should be used cautiously in those taking moderate to strong CYP3A inhibitors, as well as in patients with hepatic impairment as increased levels of the drug and its active metabolite have been seen. In those with moderate hepatic impairment (Child-Pugh class B), the area under the plasma concentration-time curve from time 0 to 12 hours for suzetrigine increased by 1.5-fold and the maximum concentration increased by 1.3-fold.¹⁰ Therefore, lower doses should be used in patients with hepatic impairment classified as Child-Pugh class B and should be avoided in patients with Child-Pugh class C cirrhosis.¹¹

FDA approval process for new pain medications

For a new medication to earn FDA approval as a non-opioid analgesic indicated for acute pain, supporting clinical trials must meet rigorous design and evidentiary standards. Investigational drugs may pursue either a general indication for acute pain by demonstrating efficacy across varied pain models or a specific indication for acute pain (e.g., postoperative pain). A general indication requires at least two well-controlled trials in different pain populations, while novel mechanisms of action may necessitate broader testing.¹²

Trials must be randomized, double-blind superiority studies, with the treatment duration reflecting the pain model and lasting at least 24 hours for multidose regimens.¹³ The primary end point should be a patient-reported measure of pain intensity, using a numerical rating scale assessed at regular intervals. The sum of pain-intensity difference is often used to evaluate cumulative pain relief over time.

The trial design must also account for rescue medication use, ensuring it does not mask the investigational drug’s effect. Additional secondary end points, such as time to onset of pain relief and need for rescue medication use, also help characterize the drug’s efficacy profile.

Pain management effectiveness

Acute postsurgical pain

The FDA approved suzetrigine based on two phase 3 randomized controlled trials that evaluated pain-control response in adults age 18 to 80 years undergoing abdominoplasty or bunionectomy who were expected to experience moderate to severe postoperative pain (verbal numerical pain score ≥ 4 of 10).¹⁴ Patients with any sensory abnormalities and those with painful physical conditions that might interfere with their ability to assess postoperative pain were not eligible. The trials also excluded patients with a history of long-term opioid or nonsteroidal anti-inflammatory use.

Patients in the abdominoplasty trial were given fentanyl for postoperative analgesia until they were lucid enough for oral medication, at which point they were randomized in a 2:2:1 fashion 15 minutes after last analgesic administration to either suzetrigine, hydrocodone bitrate and acetaminophen, or placebo.¹⁴ Patients in the bunionectomy trial had their pain initially controlled with a popliteal nerve block, so randomization occurred once the block had worn off completely. Ibuprofen 400 mg every six hours was allowed as rescue medication for breakthrough pain, but all other pain medications, including opioids, were restricted. The total amount of rescue medication use was recorded, and prerescue pain scores were carried over for six hours to ensure the integrity of the pain assessment. The primary end point was a time-weighted sum of pain-intensity difference from baseline over 48 hours. The secondary end point was the time needed to achieve a 2-point or greater reduction in pain compared with hydrocodone bitrate 5 mg and acetaminophen 325 mg.

Suzetrigine showed statistically significant superiority over placebo in reducing pain intensity over 48 hours in both the abdominoplasty (least squares mean difference 48.4, P < .0001) and bunionectomy (least squares mean difference 29.3, P = .0002) trials.¹⁴ However, suzetrigine did not meet the secondary end point of superiority over hydrocodone bitrate and acetaminophen, as no significant difference in pain scores after abdominoplasty and inferior results after bunionectomy were seen. Suzetrigine provided faster onset of clinically meaningful pain relief (≥ 2-point numeric pain rating scale reduction), with median times of 119 minutes after abdominoplasty and 240 minutes after bunionectomy, compared with placebo.

Post hoc analyses confirmed more rapid relief, especially in patients in the bunionectomy trial who had higher baseline pain. Suzetrigine also showed faster time to perceptible pain relief (≥ 1-point reduction); greater responder rates at 12, 24 and 48 hours; and higher patient global assessment scores vs placebo. Additionally, suzetrigine was associated with significantly lower rates of nausea and vomiting than hydrocodone bitrate and acetaminophen, and patients required less rescue medication after abdominoplasty, although rescue medication use was the same after bunionectomy (ibuprofen 800 mg in both groups). The results of the sum of the pain-intensity difference over 24 hours supported the primary findings, confirming suzetrigine’s efficacy in acute postsurgical pain management.¹⁴

Acute nonsurgical pain

Suzetrigine is currently only available in an oral formulation, which severely limits its perioperative use to postsurgical pain after patients resume oral intake but creates an opportunity to potentially use it for acute nonsurgical pain.

A single-arm, open-label, phase 3 study evaluated suzetrigine’s efficacy for both surgical and nonsurgical acute pain.¹⁵ Investigators included patients who presented with new acute pain (onset < 48 hours) in addition to the acute postsurgical pain populations seen in prior studies. A wider variety of surgical populations were enrolled, including otorhinolaryngology and general surgery. The modestly sized nonsurgical group (n = 34) included patients with back, extremity and facial pain. The dosing regimen was consistent with the previous phase 3 trials: 100 mg for the first dose and subsequent doses of 50 mg every 12 hours for 14 days or until pain resolved.

Good-to-excellent pain relief, the secondary outcome in this study, was experienced by 91.2% of the nonsurgical population compared with 82% of the surgical population.¹⁵ This is a strong signal that suzetrigine might have a role in managing acute nonsurgical pain, but more robust, placebo-controlled studies are required for FDA approval in this population.

Side effects

In the study that evaluated suzetrigine’s efficacy for nonsurgical pain, the primary end point was adverse events, which were seen in 36.7% of participants, but were mostly mild (27.7%) and included side effects like headache (7%), nausea (3.1%) and constipation (3.5%).¹⁵ Five patients had significant adverse events that required discontinuation, and these included accidental overdose, exacerbation of preexisting arrhythmia, nausea, rash and somnolence. These incidents were not covered in detail, but it was noted that the patients did not experience poor outcomes.

Although long-term carcinogenic potential has not been studied, animal studies of suzetrigine have shown no effect on mutagenesis or fertility.¹¹ Dependence and addiction are not expected due to the lack of central nervous system receptors, but further studies will be needed. Tolerance development and effects on bowel motility are also highly relevant primary end points for future safety studies.

All trials thus far have also been limited to short follow-up periods of only a few weeks, so phase 4 studies will show what side effects may occur with chronic use.

FDA labeling requirements

The FDA does not support vague labeling claims like “opioid sparing” because such wording lacks clarity. However, it does provide labeling guidance for more specific benefits like reducing or eliminating opioid use.^12,13 A nonopioid drug must meet three qualifications to merit label inclusion of these claims:

• Eliminates the need for opioids in a pain setting where they are typically required
• Allows patients to be discharged without opioid prescriptions when opioids are usually needed after discharge
• Reduces opioid use in conjunction with a direct clinical benefit, such as faster functional recovery or fewer opioid-related side effects (e.g., less nausea or sedation)

A drug may qualify for these labels if they are supported by data from at least two adequate, well-controlled trials and if the nonopioid medication provides analgesia comparable to that of opioids.¹³ Simply reducing opioid dose or duration is not sufficient without demonstrating a clear, meaningful benefit to the patient.

In clinical trials, suzetrigine was unable to establish superiority when compared with the comparator opioid medication, suggesting that it may be unable to eliminate opioid use in most patients.¹⁴ Additionally, over 80% of participants still required rescue ibuprofen, and opioid rescue was not assessed. Furthermore, no data were reported on discharge without opioids or long-term functional outcomes. While suzetrigine was associated with reductions in nausea and vomiting compared with the comparator opioid hydrocodone bitrate and acetaminophen, these findings were not clearly linked to reduced opioid exposure.

Opportunities and limitations

As previously mentioned, suzetrigine is only available as an oral formulation, which imposes challenges but offers opportunities at the same time. The oral formulation limits its use to the postoperative period after oral intake is resumed. An intravenous formulation might be more useful during the perioperative period, expanding its use to the intraoperative and immediate postoperative periods, and may prove to be more effective than the current formulation. On the other hand, the oral formulation makes it useful for postoperative pain management after discharge by potentially reducing or replacing opioid therapy, as well as enabling it to treat different acute and perhaps chronic nonsurgical pain indications, such as back pain, renal colic, biliary pain and so on.

As suzetrigine becomes more widely available, off-label use by physicians seems likely to increase. Current off-label use includes treatment of acute and chronic pain as well as combining it with analgesic treatment modalities to decrease the side effects of opioids by lowering their dose. Although efforts to limit perioperative opioid use are clinically valuable, current evidence indicates that inadequate postoperative pain control and preoperative opioid exposure are among the most significant predictors of both prolonged opioid use and the development of opioid use disorder.^16,17

Finally, while suzetrigine is not extremely expensive (wholesale cost is $15.50 per pill or approximately $434.00 for a two-week supply), cost-effectiveness is yet to be established.¹⁸ In addition, coverage by Medicare, Medicaid and private insurance is highly variable and depends on the formularies they use.

Suzetrigine prescribing and cost information

Based on information from references 11 and 18.

Conclusion

Although suzetrigine is a promising novel agent in the analgesic landscape, current clinical trials have not yet demonstrated its superiority over opioids in managing acute postoperative pain. Furthermore, suzetrigine’s efficacy in patients with chronic opioid use — particularly in reducing the daily dose of opioids required or improving pain outcomes — as well as the possibility of dependence remain unstudied. Suzetrigine has certainly shown it is an effective analgesic for acute pain and may have an important role as another option for multimodal postoperative analgesia regimens and for managing acute nonsurgical pain.

Drs. Divito, Bajracharya and Abdelmalak are staff in General Anesthesiology at Cleveland Clinic. Dr. Sharobeem is with the Department of Internal Medicine at McLaren Port Huron Hospital.

Disclosures

Dr. Abdelmalak has disclosed teaching and speaking for Medtronic and Mindray North America. The other authors report no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.

References

1. Shen MR, Waljee JF. Enhanced recovery after surgery protocols: Can they reduce postoperative opioid use? Ann Surg 2019; 270(6):e72. doi:10.1097/SLA.0000000000003475
2. Taylor A, McLeod G. Basic pharmacology of local anaesthetics. BJA Educ 2020; 20(2):34–41. doi:10.1016/j.bjae.2019.10.002
3. Weibel S, Jelting Y, Pace NL, et al. Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery in adults. Cochrane Database Syst Rev 2018;6(6):CD009642. doi:10.1002/14651858.CD009642.pub3
4. Jones J, Correll DJ, Lechner SM, et al. Selective inhibition of NaV1.8 with VX-548 for acute pain. N Engl J Med 2023;389(5):393–405. doi:10.1056/NEJMoa2209870
5. Amaya F, Decosterd I, Samad TA, et al. Diversity of expression of the sensory neuron-specific TTX-resistant voltage-gated sodium ion channels SNS and SNS2. Mol Cell Neurosci 2000; 15(4):331–342. doi:10.1006/mcne.1999.0828
6. Akopian AN, Sivilotti L, Wood JN. A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature 1996; 379(6562):257–262. doi:10.1038/379257a0
7. Renganathan M, Cummins TR, Waxman SG. Contribution of Na(v)1.8 sodium channels to action potential electrogenesis in DRG neurons. J Neurophysiol 2001; 86(2):629–640. doi:10.1152/jn.2001.86.2.629
8. Alsaloum M, Higerd GP, Effraim PR, Waxman SG. Status of peripheral sodium channel blockers for non-addictive pain treatment. Nat Rev Neurol 2020; 16(12):689–705. doi:10.1038/s41582-020-00415-2
9. Krafte DS, Bannon AW. Sodium channels and nociception: Recent concepts and therapeutic opportunities. Curr Opin Pharmacol 2008; 8(1):50–56. doi:10.1016/j.coph.2007.09.00
10. Rajasingham R, Qi Y. Suzetrigine, a non-opioid small-molecule analgesic: Mechanism of action, clinical, and translational science. Clin Transl Sci 2025; 18(11):e70414. doi:10.1111/cts.70414
11. Vertex Pharmaceuticals Incorporated. JOURNAVX (suzetrigine) tablets, for oral use: Prescribing information. pi.vrtx.com/files/uspi_suzetrigine.pdf. Accessed January 16, 2026.
12. U.S. Food and Drug Administration. Development of non-opioid analgesics for acute pain; draft guidance for industry; availability. Fed Regist 2022; 87(28):7843–7844.
13. U.S. Food and Drug Administration. Development of non-opioid analgesics for acute pain: Guidance for industry. Draft guidance. February 2022. www.fda.gov/media/156063/download. Accessed January 16, 2026.
14. Bertoch T, D’Aunno D, McCoun J, et al. Suzetrigine, a nonopioid Na V 1.8 inhibitor for treatment of moderate-to-severe acute pain: Two phase 3 randomized clinical trials. Anesthesiology 2025; 142(6):1085–1099. doi:10.1097/ALN.0000000000005460
15. McCoun J, Winkle P, Solanki D, et al. Suzetrigine, a non-opioid NaV1.8 inhibitor with broad applicability for moderate-to-severe acute pain: A phase 3 single-arm study for surgical or non-surgical acute pain. J Pain Res 2025;18:1569–1576. doi:10.2147/JPR.S509144
16. Wei YJ, Schmidt S, Fillingim RB, Brock G, Schmidt S, Winterstein AG. Unrelieved pain and risk of opioid use disorder or overdose in older adults prescribed opioids. Pain 2025; 166(9):e252–e260. doi:10.1097/j.pain.0000000000003589
17. Marmor MT, Hu S, Mahadevan V, Floren A, Solans BP, Savic R. Prolonged opioid use is associated with poor pain alleviation after orthopaedic surgery. J Am Acad Orthop Surg 2024; 32(13): e661–e670. doi:10.5435/JAAOS-D-24-00044
18. Business Wire, Inc. Vertex announces FDA Approval of JOURNAVX™ (suzetrigine), a first-in-class treatment for adults with moderate-to-severe acute pain. January 30, 2025. www.businesswire.com/news/home/20250109747971/en/Vertex-Announces-FDA-Approval-of-JOURNAVX-suzetrigine-a-First-in-Class-Treatment-for-Adults-With-Moderate-to-Severe-Acute-Pain. Accessed January 16, 2026.